Skip to content

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$757M-55.3%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
AbbVie logo
AbbVieABBV
$3.56B+155%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-$12.92M+75.6%
Regenxbio logo
RegenxbioRGNX
-$77.42M-337%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$25.55M-20.7%

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Calculated from Immix Biopharma, Inc.’s reported figures.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s free cash flow?
Immix Biopharma, Inc. (IMMX) reported free cash flow of -$9.86M in Q1 2026.
How has Immix Biopharma, Inc.'s free cash flow changed year-over-year?
Immix Biopharma, Inc.'s free cash flow decreased by 462.5% year-over-year, from -$1.75M to -$9.86M.
What is the long-term trend for Immix Biopharma, Inc.'s free cash flow?
Over 2 years (2021 to 2025), Immix Biopharma, Inc.'s free cash flow has grown at a 293.8% compound annual growth rate (CAGR), from -$1.59M to -$24.66M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.